期刊文献+

垂体瘤基础研究的最新进展:从分子机制到临床应用

Latest advances in basic research of pituitary neuroendocrine tumors:from molecular mechanisms to clinical applications
暂未订购
导出
摘要 垂体瘤是一种复杂而异质性大的神经内分泌肿瘤,其发生和发展涉及多种分子机制和信号通路。近年来,随着分子遗传学技术、单细胞测序和人工智能的快速发展,垂体瘤的研究取得了显著进展。这些技术揭示了肿瘤的分子异质性、关键基因突变和肿瘤微环境的特性,为精准分型和个体化治疗奠定了基础。在治疗领域,内镜技术推动了手术策略的不断优化,靶向治疗和免疫治疗的探索为侵袭性垂体瘤患者提供了新的希望。本综述聚焦于垂体瘤研究的最新进展,包括核心分子机制、免疫微环境的角色、人工智能辅助的风险预测,以及新型治疗方法的实践与展望,为未来的精准医学发展提供参考。 Pituitary neuroendocrine tumors(PitNETs)are complex and heterogeneous neuroendocrine tumors,whose development and progression involve multiple molecular mechanisms and signaling pathways.In recent years,significant advances have been made in the research of PitNETs,thanks to the rapid development in molecular genetics technology,single-cell sequencing,and artificial intelligence.These technologies have unveiled the molecular heterogeneity of the tumors,key gene mutations,and the characteristics of the tumor microenvironment,laying the groundwork for precise classification and personalized treatment.In the field of treatment,endoscopic technology has driven the optimization of surgical strategies,while the exploration of targeted therapy and immunotherapy provides new hope for invasive PitNETs.This review focuses on the latest advances in PitNET research,including core molecular mechanisms,the role of the immune microenvironment,AI-assisted risk prediction,and the practice and prospects of novel therapeutic methods,providing a reference for the future development of precision medicine in PitNETs.
作者 王镛斐 张启麟 WANG Yongfei;ZHANG Qilin(Neurosurgery Department,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处 《中华神经外科疾病研究杂志》 2025年第2期1-6,共6页 Chinese Journal of Neurosurgical Disease Research
基金 中国医学科学院医学与健康科技创新工程(2023-I2M-C&T-B-125)。
关键词 垂体瘤 分子遗传学 人工智能 手术 免疫治疗 Pituitary neuroendocrine tumors(PitNETs) Molecular genetics Artificial intelligence Surgery Immunotherapy
  • 相关文献

参考文献5

二级参考文献41

  • 1Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing's disease: the state of the art. Endocrine 2014; 47:9- 20.
  • 2Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367:1605-1617.
  • 3Melmed S. The Pituitary. 3rd ed. Amsterdam: Elsevier 2011:712-713.
  • 4Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526-1540.
  • 5Billet BM, Grossman AB, Stewart PM, et al. Treatment of ad- renocorticotropin-dependent Cushing's syndrome: a consen- sus statement. J Clin Endocrinol Metab 2008; 93:2454-2462.
  • 6Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brgl and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20:2871-2886.
  • 7Lidhar K, Korbonits M, Jordan S, et aL Low expression of the cell cycle inhibitor p27Kipl in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors, d Clin Endocrinol Metab 1999; 84:3823-3830.
  • 8Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function ofp27(Kipl). Cell 1996; 85:721-732.
  • 9Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expres- sion of epidermal growth factor receptor in neoplastic pitu- itary cells: evidence for a role in corticotropinoma cells. J Endocrino12004; 183:385-394.
  • 10Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a ther- apeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J CIin lnvest 2011; 121:4712-4721.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部